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AbstrACt
Objective We aimed to compare patient’s and physician’s 
ratings of inhaled medication adherence and to identify 
predictors of patient- physician discordance.
Design Baseline data from two prospective multicentre 
observational studies.
setting 29 allergy, pulmonology and paediatric secondary 
care outpatient clinics in Portugal.
Participants 395 patients (≥13 years old) with persistent 
asthma.
Measures Data on demographics, patient- physician 
relationship, upper airway control, asthma control, asthma 
treatment, forced expiratory volume in one second (FEV
1) 
and healthcare use were collected. Patients and physicians 
independently assessed adherence to inhaled controller 
medication during the previous week using a 100 mm 
Visual Analogue Scale (VAS). Discordance was defined as 
classification in distinct VAS categories (low 0–50; medium 
51–80; high 81–100) or as an absolute difference in VAS 
scores ≥10 mm. Correlation between patients’ and physicians’ 
VAS scores/categories was explored. A multinomial logistic 
regression identified the predictors of physician overestimation 
and underestimation.
results High inhaler adherence was reported both by patients 
(median (percentile 25 to percentile 75) 85 (65–95) mm; 53% 
VAS>80) and by physicians (84 (68–95) mm; 53% VAS>80). 
Correlation between patient and physician VAS scores was 
moderate (rs=0.580; p<0.001). Discordance occurred in 56% 
of cases: in 28% physicians overestimated adherence and 
in 27% underestimated. Low adherence as assessed by the 
physician (OR=27.35 (9.85 to 75.95)), FEV
1 ≥80% (OR=2.59 
(1.08 to 6.20)) and a first appointment (OR=5.63 (1.24 to 25.56)) 
were predictors of underestimation. An uncontrolled asthma 
(OR=2.33 (1.25 to 4.34)), uncontrolled upper airway disease 
(OR=2.86 (1.35 to 6.04)) and prescription of short- acting beta- 
agonists alone (OR=3.05 (1.15 to 8.08)) were associated with 
overestimation. Medium adherence as assessed by the physician 
was significantly associated with higher risk of discordance, both 
for overestimation and underestimation of adherence (OR=14.50 
(6.04 to 34.81); OR=2.21 (1.07 to 4.58)), while having a written 
action plan decreased the likelihood of discordance (OR=0.25 
(0.12 to 0.52); OR=0.41 (0.22 to 0.78)) (R2=44%).
Conclusion Although both patients and physicians report 
high inhaler adherence, discordance occurred in half of cases. 
Implementation of objective adherence measures and effective 
communication are needed to improve patient- physician 
agreement.
bACkgrOunD
Inhaled controller medications are the 
cornerstone of effective asthma treatment,1 
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strengths and limitations of this study
 ► Data from two multicentre studies with a similar design conducted 
at 29 secondary care outpatient clinics.
 ► Estimates of inhaled medication adherence were only based on 
Visual Analogue Scales, but these simple measures could be easily 
implemented during medical visits.
 ► Patient and physician estimates of adherence were not compared 
with objective data and were assessed only at one time- point.
 ► Predictors of discordance were identified in a multinomial model, 
but results may not be generalisable as patients were recruited by 
convenience sampling.
with established benefits in decreasing severity and 
frequency of symptoms as well as exacerbations.2 3 
However, to achieve these benefits, daily adherence to the 
prescribed inhaled medications is of critical importance.
Adherence rates in patients with asthma are known 
to be low, both in paediatric and adult studies.4 5 Subop-
timal adherence to inhaled medication is associated 
with poor health outcomes, including lack of symptom 
control, exacerbations, emergency department visits and 
hospitalisations, leading to disease progression, addi-
tional social burden and health costs.6 To improve these 
health outcomes, it is crucial to promptly identify poorly 
adherent patients during medical visits,7 enabling physi-
cians to address adherence barriers early and avoiding 
unnecessary additional diagnostic procedures and adjust-
ments in medication. However, this is quite challenging 
as there is no commonly accepted approach to assess 
adherence.
Distinct methods have been used, such as evaluation 
of medical/dispensing records, use of electronic moni-
toring devices and reliance on self- reports.8–10 The first 
two methods have limited feasibility for routine use in 
clinical practice and resource- constrained settings. Self- 
reports, although subjective, are still considered one of 
the preferred methods to continuously monitor adher-
ence as they are simple, cheap and minimally intrusive.11 12 
One example is the use of a single item Visual Analogue 
Scale (VAS), which has shown to provide estimates of 
adherence comparable with pill counts and dispensing 
records11 13 and is easily applied during medical visits.14 
However, reliance on VAS also has its limitations. Patients 
tend to overestimate their level of adherence.11 13 Addi-
tionally, physicians have been found to be inaccurate 
in estimating patients’ adherence when using VAS.15 16 
These limitations may generate patient- physician discor-
dance and impair the identification of patients with poor 
adherence. In turn, this might influence patient satisfac-
tion and compromise shared decision making and thera-
peutic adjustments.17
Evidence is lacking on the degree and characteristics 
of discordance between patients and physicians in rela-
tion to the assessment of inhaled medication adherence. 
In other chronic diseases, patients’ clinical status, disease 
severity and age are known predictors of patient- physician 
discordance regarding medication adherence.18 19 The 
identification of the level of discordance as well as char-
acteristics associated with patient- physician discordance 
are essential to delineate effective strategies to maxi-
mise patient- physician agreement and improve clinical 
decisions. Therefore, we aimed to (1) compare patient’s 
and physician’s ratings of inhaled medication adher-
ence using VAS and (2) to identify predictors of patient- 
physician discordance.
MethODs
study design
Initial face- to- face visit and 1- week telephone interview 
data from two prospective observational studies of the 
Inspirers project were analysed (view online supple-
mentary table 1).20 This project addresses the topic of 
adherence to asthma inhalers among adolescents and 
adults with persistent asthma. A convenience sample was 
recruited between November 2017 and June 2018 at 29 
allergy, pulmonology and paediatric secondary care outpa-
tient clinics in Portugal. The studies were approved by the 
ethics committees of all participating centers. The study 
is reported according to Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) guide-
lines.21 Eligible patients were approached by physicians 
during medical visits. Adult patients signed a consent 
form. Adolescents signed an assent form, and a parental 
consent form was also obtained.
Patients
Patients were included if they had a previous medical 
diagnosis of persistent asthma, were at least 13 years old 
(13–17 years adolescents; ≥18 years adults) and had an 
active prescription for an inhaled controller medica-
tion for asthma. All inhaled controller treatments were 
allowed, and there was no change in any prescribed medi-
cation in relation to the participation in these studies. 
Patients were excluded if they had a diagnosis of a chronic 
lung disease other than asthma or a diagnosis of another 
significant chronic condition with possible interference 
with the study aims.
Patient and public involvement
Patients were not involved in this study.
Data collection
During the initial face- to- face visit, data were collected 
from both patients and physicians. Physicians answered 
a questionnaire including: assessment of patients’ asthma 
control according to the Global Initiative for Asthma 
(GINA)1; last known value of percent predicted forced 
expiratory volume in one second (FEV1) and respec-
tive date; number of exacerbations, defined as episodes 
of progressive increase in shortness of breath, cough, 
wheezing and/or chest tightness, requiring change in 
maintenance therapy22; use of healthcare resources 
namely, number of unscheduled medical visits (primary 
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care, secondary care or emergency department) and 
number of hospital admissions; and length of physician- 
patient relationship. Physicians also reported on the 
patients’ current asthma treatment, including inhaled and 
oral medication, allergen immunotherapy and biological 
therapy. Medication was grouped by active substance in 
classes: inhaled corticosteroids (ICS), long- acting beta- 
agonists (LABA), ICS and LABA (ICS/LABA), long- acting 
muscarinic receptor antagonists (LAMA), short- acting 
beta- agonists (SABA), short- acting muscarinic- antagonists 
(SAMA), anti- leukotrienes, xanthines and oral corticoste-
roids. Reliever therapy with beta- agonist was classified 
based on the prescription of SABA and/or LABA and 
accounting for the type of prescribed LABA, considering 
that maintenance and reliever therapy (MART) is only 
recommended with formoterol.1 We stratified reliever 
therapy into three groups: without prescribed SABA or 
fast- acting LABA recommended for MART (includes 
patients prescribed a LABA other than formoterol); with 
SABA alone (also includes patients prescribed a LABA 
other than formoterol) and with LABA that allows MART 
(with or without concomitant SABA). In addition, we clas-
sified asthma severity in accordance with GINA treatment 
steps.1 Patients and physicians independently assessed 
patient global adherence to inhaled controller medica-
tion for asthma during the previous week using a VAS, 
ranging from 0 (worst) to 100 (best) mm.23 Both filled in 
their respective VAS in distinct case report forms, without 
any specific instructions, and at distinct moments, being 
kept blind to each other’s response.
Demographic data—age, gender, smoking habits—
were also collected from patients during the face- to- 
face visit. Upper airway control was assessed using the 
Control of Allergic Rhinitis and Asthma Test upper airway 
(CARAT- UA) subscore.24 The CARAT- UA subscore ranges 
from 0 to 12 points, with >8 points being indicative of 
good control.25
Approximately 1 week later, through a telephone inter-
view, patients were asked to characterise the patient- 
physician relationship, namely if patient’s preferences 
were considered at the time of inhaler prescription, if 
they had their inhaler technique reviewed during the last 
12 months and if they had a written asthma action plan.
statistical analysis
Descriptive statistics were used to characterise the 
sample. Normality of each variable was investigated with 
Kolmogorov- Smirnov tests and visual analysis of histo-
grams. Inhaler adherence VAS scores were compared 
by pairing patients and physicians using Wilcoxon 
signed- rank tests and between adolescents and adults, 
using Mann- Whitney U tests, both considering patients 
and physicians scores. Intraclass correlation coefficient 
(ICC) and Bland- Altman plots were used to assess rela-
tive and absolute reliability of inhaler adherence VAS 
scores from patients and physicians. ICC was interpreted 
as excellent (ICC >0.9), good (ICC=0.75–0.9), moderate 
(ICC=0.5–0.75) or poor (ICC <0.5).26 27 Correlations with 
Spearman’s rho were also used to explore the relation-
ship between patients and physicians VAS scores. Spear-
man’s rho was interpreted as negligible (0–0.30), low 
(0.3–0.5), moderate (0.5–0.7), high (0.7–0.9) and very 
high (0.9–1).28
VAS scores were further categorised using cut- offs 
of 50% and 80%, generating three VAS categories: low 
(0–50 mm), medium (51–80 mm) and high (81–100 mm) 
adherence. These cut- offs are frequently used for differ-
entiation of adherence groups.29–33 To determine the 
agreement on VAS categories between patients and 
physicians, the percentage of agreement and weighted 
Cohen’s kappa were used.34 Cohen’s kappa values were 
interpreted as follows: <0, no agreement; 0–0.20, slight; 
0.21–0.40, fair; 0.41–0.60, moderate; 0.61–0.80, substan-
tial and 0.81–1.0, almost perfect agreement.34
Discordance was defined as (1) category discordance, 
classification in distinct VAS categories or (2) value 
discordance, as an absolute difference in VAS scores 
≥10 mm. A difference of 10 mm has been widely accepted 
as a minimum threshold for clinical relevance.35–37 The 
direction of the discordance was characterised as physi-
cian overestimation of patient’s adherence (higher VAS 
scores by at least 10 mm or higher VAS category) or, 
inversely, as physician underestimation (lower VAS scores 
by at least 10 mm or lower VAS category than the patients’ 
perspective). Univariate multinomial logistic regressions 
were used to identify possible patient, disease or treat-
ment characteristics predicting the discordance outcome 
(0=concordance, used as reference; 1=physician under-
estimation; 2=physician overestimation). Variables with 
p<0.25 at univariate analysis and informative variables 
linked to these variables (eg, last percent predicted FEV1 
and respective date) were used in a multivariate multino-
mial logistic regression.38 When two candidate variables 
(predictors) were highly correlated, such as patient and 
physician adherence ratings, only one was included in 
the model.39 The final model was obtained using a back-
ward stepwise method of variable selection. Adjusted OR 
and 95% CI (OR (95% CI)) are presented. The overall 
model was evaluated using the goodness- of- fit tests and 
the Nagelkerke’s R- square.
Statistical analyses were performed using IBM SPSS 
Statistics V.25.0 (IBM Corporation, Armonk, New York, 
USA) and plots were created using GraphPad Prism V.6.0 
(GraphPad Software, La Jolla, California, USA). The level 
of significance was set at 0.05.
results
Participants
From the 413 patients included in both studies, 395 (96%) 
had complete data on inhaled medication adherence and 
were considered in this work. Patients had a median age 
(percentile 25 to percentile 75) of 28 (16–46) years and 
were mainly female (61%). Most were on ICS/LABA combi-
nation therapy (n=330; 84%) and used only one inhaler 
(n=265; 67%). According to the GINA classification, nearly 
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Table 1 Participants’ characteristics (n=395)
Total (n=395) Adolescents (n=126) Adults (n=269)
Age, median (P25–P75) 28 (16–46) 15 (14–16) 40 (27–52)
Female 242 (61) 57 (45) 185 (69)
Smoking status
  Never smoker 301 (76) 115 (91) 186 (69)
  Ex- smoker 65 (17) 8 (6) 57 (21)
  Current smoker 27 (7) 3 (2) 24 (9)
Inhaled medication
  ICS/LABA 330 (84) 89 (71) 241 (90)
  ICS 66 (17) 37 (29) 29 (11)
  LAMA 50 (13) 3 (2) 47 (18)
  LABA 11 (3) 2 (2) 9 (3)
  LABA/LAMA 3 (1) 0 3 (1)
  SABA 79 (20) 36 (29) 43 (16)
  SAMA 3 (1) 0 3 (1)
Number of prescribed inhalers
  1 265 (67) 86 (68) 179 (67)
  2 113 (29) 40 (32) 73 (27)
  ≥3 16 (4) 0 16 (6)
Oral medication
  Anti- leukotrienes 209 (53) 62 (49) 147 (55)
  Xanthines 12 (3) 0 12 (5)
  Oral corticosteroids 8 (2) 0 8 (3)
Allergen immunotherapy 72 (18) 31 (25) 41 (15)
Biological therapy 24 (6) 1 (1) 23 (9)
GINA assessment symptom control
  Well- controlled 209 (53) 58 (46) 151 (56)
  Partly controlled/uncontrolled 184 (47) 67 (53) 117 (44)
≥1 exacerbations past year 195 (49) 70 (56) 125 (47)
≥1 unscheduled medical visits past 
year
120 (30) 38 (30) 82 (31)
≥1 hospital admissions past year 15 (4) 2 (2) 13 (5)
Values are shown as n (%) unless otherwise indicated.
GINA, Global Initiative for Asthma; ICS, inhaled corticosteroids; LABA, long- acting beta- agonists; LAMA, long- acting muscarinic receptor 
antagonists;P25–P75, percentile 25 to percentile 75; SABA, short- acting beta- agonists; SAMA, short- acting muscarinic- antagonists.
half of participants had their asthma not well- controlled 
(n=184; 47%) and had at least one exacerbation during the 
previous year (n=195; 49%). Characteristics of the partici-
pants are summarised in table 1.
Inhaler adherence—patient reported and physician 
assessment
Inhaler adherence was considered high both by patients 
(median 85 (65–95) mm, VAS>80 53%) and by physicians 
(84 (68–95) mm, VAS>80 53%). VAS scores were signifi-
cantly lower in adolescents when compared with adults, 
in the perspective of both patients (median 80 vs 88, 
p<0.001) and physicians (median 79 vs 88, p<0.001). The 
median difference between patients and physicians VAS 
scores was significantly higher for adolescents than adults 
(median 11 (5–20) vs 9 (3–20); p=0.025). Correlation 
between patient and physician VAS scores was moderate 
(rs=0.580; p<0.001) (figure 1). A lower correlation was 
found for adolescents (rs=0.462 vs adults rs=0.572). The 
relative reliability between patients and physicians scores 
was moderate, with an ICC of 0.63 (95% CI 0.57 to 0.69). 
Reliability in adolescents was 0.52 (0.38 to 0.64) and in 
adults 0.66 (0.59 to 0.73). Bland and Altman plots are 
shown in figure 2. There was reasonable agreement, with 
bias close to zero and quite large limits of agreement 
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Figure 1 Scatter plot showing the relationship between patients and physicians estimates of inhaler adherence (n=395), 
with the black line representing perfect agreement; the red and orange lines representing the cut- offs of 50 and 80—in 40% 
cases both patients and physicians classified adherence to inhaler treatments in previous week higher than 80%, in 15% 
cases between 51% and 80% and in 9% cases below 50%. Physicians underestimated adherence in 19% and overestimated 
adherence in 17% of the participants.
Figure 2 Bland- Altman plots of inhaler adherence Visual Analogue Scale (VAS) scores between patients and physicians in the 
total sample (n=395), in adolescents (n=126) and in adults (n=269). The solid lines represent the bias, and the dashed lines show 
the 95% limits of agreement.
(LoA) (bias 0.15, SD 20.5; 95% LoA −40.1–40.4). Consid-
ering the two age groups, a slightly better agreement 
for adults (bias 0.52, SD 20.3; 95% LoA −39.3–40.4) in 
comparison with adolescents (bias −0.64, SD 20.9; 95% 
LoA −41.7–40.4) was found.
Value discordance was high (n=211; 53%), with physi-
cians overestimating adherence in 26% (n=102) of cases 
and underestimating it in 27% (n=109). Category discor-
dance occurred in 36% (n=142) of cases, with physicians 
overestimating adherence in 17% (n=66) of cases and 
underestimating in 19% (n=76) (table 2). Based on cate-
gory discordance, a weighted Cohen’s kappa of 0.46 (0.38 
to 0.54) (p<0.001) was found, reflecting moderate agree-
ment. The category discordance between patients and 
physicians was higher in adolescents (41%) than in adults 
(34%). Weighted kappa was 0.36 (0.22 to 0.50) for adoles-
cents and 0.48 (0.39 to 0.58) for adults, demonstrating a 
fair and moderate agreement, respectively.
Total discordance occurred in 56% of cases: 78 (20%) 
based on value discordance only, 9 (2%) based on cate-
gory discordance only and 133 (34%) classified as discor-
dant using both methods. In 28% of the cases, physicians 
overestimated adherence and in 27% underestimated 
it. Unadjusted ORs estimating the association between 
each variable and direction of physician discordance are 
presented in online supplementary table 2. Adjusted ORs 
of the multivariate multinomial model are summarised in 
table 3. Uncontrolled asthma (OR 2.33 (1.25 to 4.34)), 
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Table 2 Agreement on VAS categories between patients and physicians (n=395)—64% were in the same category, 30% 
differed one category and 6% differed two categories
Patient VAS category
High Medium Low Total
Physician
VAS category
High 156 (40%) 41 (10%) 13 (3%) 210 (53%)
Medium 43 (11%) 61 (15%) 12 (3%) 116 (29%)
Low 10 (3%) 23 (6%) 36 (9%) 69 (18%)
Total 209 (53%) 125 (32%) 61 (15%) 395 (100%)
Values in bold represent perfect agreement.
VAS, Visual Analogue Scale.
Table 3 Multivariate multinomial model to explain physician overestimation or underestimation of patient’s adherence 
(patient- physician concordance used as reference, n=142, 45%)
Physician overestimation
(n=86; 27%)
Physician underestimation
(n=86; 27%)
P value*OR (95% CI) P value OR (95% CI) P value
Adolescents (Ref=Adults) 0.84 (0.43 to 1.68) 0.630 1.82 (0.87 to 3.82) 0.110 0.132
Reliever therapy (Ref=No SABA 
nor LABA with MART possible)
  0.016
  SABA alone 3.05 (1.15 to 8.08) 0.025 0.63 (0.21 to 1.89) 0.408
  LABA with MART possible 2.14 (0.97 to 4.72) 0.059 0.53 (0.24 to 1.17) 0.116
Adherence VAS categories by 
physicians (Ref=High)
  <0.001
  Medium 2.21 (1.07 to 4.58) 0.033 14.50 (6.04 to 34.81) <0.001
  Low 0.84 (0.30 to 2.34) 0.741 27.35 (9.85 to 75.95) <0.001
Uncontrolled upper airways 
with CARAT(Ref=Controlled)
2.86 (1.35 to 6.04) 0.006 0.89 (0.41 to 1.97) 0.782 0.008
Uncontrolled asthma according 
to GINA (Ref=Well- controlled)
2.33 (1.25 to 4.34) 0.008 1.39 (0.67 to 2.91) 0.378 0.026
FEV1 % predicted ≥80% 
(Ref=<80%)
1.75 (0.87 to 3.52) 0.115 2.59 (1.08 to 6.20) 0.033 0.057
Spirometry past year (Ref=No) 1.92 (0.99 to 3.73) 0.054 0.81 (0.40 to 1.64) 0.554 0.052
First medical visit (Ref=No) 0.80 (0.17 to 3.79) 0.779 5.63 (1.24 to 25.56) 0.025 0.041
Written asthma action plan 
(Ref=No)
0.41 (0.22 to 0.78) 0.006 0.25 (0.12 to 0.52) <0.001 <0.001
314 patients included in this analysis as clinical information was incomplete for 81 patients, mainly lacking information on FEV1. Significant 
values marked in bold.
*Likelihood ratio tests.
CARAT, Control of Allergic Rhinitis and Asthma Test; FEV1, forced expiratory volume in one second; GINA, Global Initiative for Asthma; LABA, 
long- acting beta- agonists; MART, maintenance and reliever therapy; SABA, short- acting beta- agonists; VAS, Visual Analogue Scale.
uncontrolled upper airway disease (OR 2.86 (1.35 to 
6.04)) and prescription of SABA alone (OR 3.05 (1.15 
to 8.08)) were predictors of overestimation. Low adher-
ence rated by the physician (OR 27.35 (9.85 to 75.95)), 
FEV1 ≥80% (OR 2.59 (1.08 to 6.20)) and a first appoint-
ment (OR 5.63 (1.24 to 25.56)) predicted underestima-
tion. Medium adherence as assessed by the physician was 
significantly associated with higher risk of both physician 
overestimation and underestimation (OR 14.50 (6.04 to 
34.81) and OR 2.21 (1.07 to 4.58), respectively), while 
having a written action plan decreased the likelihood of 
discordance (OR 0.25 (0.12 to 0.52) and OR 0.41 (0.22 to 
0.78), respectively). Pearson χ2 (p=0.431) and deviance 
(p=0.721) showed that the multinomial logistic regression 
model adequately fitted the data. This model explained 
44% of the variance in patient- physician discordance and 
correctly classified 63% of cases.
DIsCussIOn
To the authors’ knowledge, this is the first study investi-
gating patient and physician agreement on adherence to 
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asthma inhalers. We found that although both patients and 
physicians reported high inhaler adherence, their degree 
of adherence was discordant in half of the cases. We have 
also identified in a multinomial model the predictors of this 
discordance. Uncontrolled asthma, uncontrolled upper 
airway disease and prescription of SABA alone were predic-
tors of physician’s overestimation of adherence, while low 
adherence as assessed by the physician (VAS≤50 mm), FEV1 
≥80% and being on a first appointment were predictors of 
underestimation. Medium inhaler adherence rated by the 
physician (VAS 51–80 mm) and absence of a written action 
plan were predictors of both physician overestimation and 
underestimation.
Self- reported adherence to inhaled medications was 
found to be high (median 85), which is in line with find-
ings from previous studies on adherence to inhaled medi-
cation (mean 90)32 33 and to oral medications (mean or 
median values between 84 and 100).11 13 19 40–44 Physicians’ 
perception of the extent of adherence to inhaled medi-
cation was also high (median 84 mm), in agreement with 
prior reports.14 18 42–44 Adherence self- reported by adoles-
cents and assessed by their physicians was lower in compar-
ison with adults. This was somewhat expected as previous 
research showed that adolescents tend to be less adherent 
to inhaled asthma therapy when compared with younger 
children or adults.45 46 Irrespective of the patients’ age, it 
is possible that both patients’ and physicians’ adherence 
estimates were overestimating real adherence, as previous 
research showed lower adherence levels to inhaled medica-
tions for asthma when using objective assessment methods4 
and overestimation of subjective measures of adher-
ence when compared with objective measures.15 18 47–49 
However, in the present study, we did not collect objective 
data on inhaler adherence to support this assumption.47 
This was mainly due to the fact that currently available 
objective methods (eg, medical/dispensing records, elec-
tronic monitoring devices) required laborious analysis 
by physicians and were costly to implement in clinical 
practice. There is an urgent need to develop and validate 
low- cost, ubiquitous and easy- to- disseminate tools to objec-
tively measure inhaler adherence. Mobile applications 
that allow patients to record their inhaler adherence and 
share it with their physician may be promising solutions. 
Some apps with these features are already available, such 
as AsthmaMD (https://www. asthmamd. org/), Asthma 
Coach (http:// myhealthapps. net/ app/ details/ 317/ 
asthma- coach) and InspirerMundi (https:// play. google. 
com/ store/ apps/ details? id= com. bloomidea. inspirers& 
hl= pt_ PT). InspirerMundi app, besides traditional daily 
self- report of medication intake, has an additional inhaled 
medication adherence detection tool, using the smart-
phone camera and advanced image processing, which vali-
dates inhaler use through dose tracking.50 The Inspirers 
research project, in which the present work is included, is 
developing the InspirerMundi app and plans to assess its 
feasibility and validity in real- life studies.
Discordance was found in 36% (VAS categories) and 53% 
of cases (VAS difference ≥10 mm) and fair- to- moderate 
agreement was found between patient and physician 
reports. In other conditions requiring daily therapy, such 
as HIV, similar discordance rates have been found.18 51 This 
discordant perspective regarding medication adherence is 
of particular concern as it may limit evaluation and discus-
sion of treatment decisions between patients and their 
physicians (shared decision making),17 which is likely to 
have a negative impact on diagnostic and therapeutic deci-
sions such as unnecessary additional procedures and adjust-
ments to medication regimen. In future, implementation of 
more effective patient- physician communication together 
with the use of objective adherence measures at the time of 
the medical encounter may improve agreement.
Irrespective of the method used to define discordance, 
we found a balance between physicians overestimation 
and underestimation of inhaler adherence compared with 
patient self- reported adherence. In studies conducted 
in other chronic diseases, such as hypertension, oste-
oporosis or HIV, physicians tended to overestimate 
adherence.15 18 47 One can speculate that this compared 
overestimation and underestimation may be related to a 
higher awareness of the barriers to inhaled medication 
adherence of physicians treating patients with asthma. 
However, studies with objective adherence measures eval-
uating the predictors for physicians underestimation and 
overestimation of adherence are needed.
The discordance in the perceptions of inhaler adher-
ence may have several reasons. In this study, having a 
written asthma action plan was associated with a reduc-
tion in the likelihood of discordance. If patients and 
physicians at a certain point of their relationship have 
agreed on an action plan, they will be more likely to imple-
ment effective communication, partnership working and 
shared decision making during medical visits, which is 
also reflected in closer estimates of inhaler adherence. 
Indeed, effective communication was one of the main 
themes identified by patients as helping the promo-
tion and/or use of action plans.52 In the patients’ view, 
good communication meant being listened to, feeling 
respected and having their own knowledge and experi-
ence of asthma recognised by physicians during clinical 
encounters.52 The same argument may also explain why 
absence of previous patient- physician relationship was 
associated with underestimation of adherence. Imple-
mentation of effective communication in the first visit is 
challenging, as it is a critical time for a systematic collec-
tion of diverse information.53 First visits were also previ-
ously linked to greater discordance between patients and 
physicians.18 53
Other predictors of overestimation were prescription of 
SABA alone, uncontrolled asthma and uncontrolled upper 
airway disease. Although in this study we have not quanti-
fied the use of reliever therapy, the inclusion of SABA alone 
in the physician- reported therapeutic plan can be regarded 
as a proxy of SABA use. These associations suggest that 
physicians consider patients with poor outcomes or using 
SABA as being more likely to adhere to the prescribed 
control inhaler. However, this is contrary to the available 
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evidence showing that SABA can adversely affect adher-
ence to anti- inflammatory treatment and contribute to 
high levels of poorly controlled asthma.54 Thus, we cannot 
exclude a possible reverse causality with overestimation 
itself being a marker of underlying lack of effective patient- 
physician communication, which might lead to impaired 
physician perception of the need for control medication 
adjustments and contribute to worse patient outcomes, 
including poor disease control and need for SABA. Never-
theless, the estimation of adherence in light of disease 
control might be highly misleading, as patients could have 
their disease controlled even with dosages much lower than 
prescribed, whereas others who take their prescribed medi-
cation may not.19 Indeed, some studies demonstrate that 
asthma control is not directly associated with adherence 
behaviours.55 56 The same argument may also explain why 
an FEV1 ≥80%, also related to good asthma control,
57 58 was 
associated with physician underestimation of adherence, 
suggesting that physicians believe that patients who have 
better lung function are more prone to forget or reduce 
medication intake. It is known that, in the absence of objec-
tive adherence data, physicians commonly rely on patients’ 
health status to estimate adherence. This is not exclusive 
of physicians managing patients with asthma and occurs 
also in other diseases.15 19 Nevertheless, this is a dangerous 
assumption that may lead to unnecessary and inadequate 
changes in the medication regimen.
Our study has some limitations. Although data come 
from two multicentre studies involving 29 secondary care 
outpatient clinics, patients were recruited by convenience 
sampling. Therefore, the findings may not be generalis-
able to all patients with persistent asthma. Future studies 
can confirm or negate these results, preferably recruiting 
patients from different healthcare settings, including 
primary care, and using consecutive or random sampling. 
Patient and physician estimates were assessed only at 
one time- point and based on a single type of measure 
(VAS). Future long- term studies could use VAS together 
with other adherence subjective measures, such as the 
Eight- Item Morisky Medication Adherence Scale,59 and 
with complementary questionnaires on adherence issues 
such as medication beliefs60 or knowledge.61 Also, future 
research could compare subjective estimates with objec-
tive adherence measures, ideally simple to use during 
clinical encounters. When interpreting the agreement 
between patients and physicians, we need to be aware 
that kappa is highly sensitive to the distribution of the 
marginal totals and could produce unreliable results. 
Also, we need to take into account that each physician 
rated several patients and a possible physician- cluster 
effect might have occurred. In addition, as there is no 
standardised way to define discordance, we used two 
approaches to define discordance, both based on previ-
ously used and generally accepted cut- offs,29–31 35–37 which 
we believe make our results more robust. Nevertheless, 
more research is needed on how to define discordance. 
Regarding discordance prediction, some outcomes of 
interest occurred frequently (>10%) and this may lead to 
overestimation of the relative risk. This problem has been 
identified in cohort studies of common outcomes,62 and 
thus our results need to be interpreted with caution.
In conclusion, although both patients and physicians 
report high inhaler adherence, discordance occurs in half 
of cases. This study has identified some predictors that 
can help to improve the understanding on this discor-
dance. Implementation of objective adherence measures 
and effective communication are needed to improve the 
patient- physician agreement and therapeutic decisions.
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